Zivo Bioscience, Inc. · OTC:ZIVO

Zivo Bioscience — Shareholder Meeting (October 2021)

23 slides from Zivo Bioscience's shareholder meeting presentation, Oct 12, 2021

  1. Slide 1: ZIVO Bioscience, Inc. Annual Shareholders Meeting

    ZIVO Bioscience, Inc. Annual Shareholders Meeting Detroit, Michigan October 2021 Transformative Opportunities in Immune Health & Nutrition

  2. Slide 2: Notice: Safe Harbor Statement

    e Notice Safe Harbor Statement Except for any historical information, the matters discussed in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements

  3. Slide 3: 2021 Annual Shareholder Meeting

    2021 Annual Shareholder Meeting October 12, 2021 WELCOME Meeting Open CFO REPORT Keith R. Marchiando Chief Financial Officer ZzIve BIOSCIENCE

  4. Slide 4: CEO Report to Shareholders

    2021 Annual Shareholders Meeting October 12, 2021 CEO Report to Shareholders Andrew A. Dahl President & Chief Executive Officer ZzIve BIOSCIENCE

  5. Slide 5: A new path to optimal health

    ZIVO Bioscience, Inc. Anew path to optimal health We are creating novel drug candidates and functional food ingredients designed to boost immune health in humans and animals ZIVO BIOSCIENCE, INC. NASDAQ: :ZIVO; ZIVOW a Da

  6. Slide 6: Notice to Shareholders and Investors

    2020 Annual Shareholders Meeting Notice to Shareholders and Investors This presentation and any Exhibits to it contain forward-looking statements that involve risks and uncertainties. These statements reflect the Company's future plans, objectives, expectations and intentions, and the assumptions un

  7. Slide 7: 2021 — The Watershed Year

    2021 — The Watershed Year Biotech Molecules Biotechnolog Compounds y Complexes AgTech Agricultural Technology Algal Biomass wa" Extracts Dry Mixes ZzIve BIOSCIENCE Strongest Position Ever Capital funding completed Robust intellectual property portfolio Commercial initiatives underway Pursuing licens

  8. Slide 8: Public Offering and Up-Listing to Nasdaq Exchange

    ZzIve e Public Offering and Up-Listing to Nasdaq Exchange Bioscience A Summary of Events BiOtECH jcsecscs : softer Biotechnolog Gampouens June 2, 2021 registered public offering y fae underwritten by Maxim Group = Gross proceeds of $13.8M AgTech = Net proceeds of $12.2M Agricultural Technology Algal

  9. Slide 9: Biotech Molecules: Production, Validation and New Applications

    e B i otech Molecules ‘Compounds Complexes Biotechnolog ¥. Production, Validation and New Applications Fence Manufacturing Development & Feasibility = Development work for fermentation processes concluded 2021 = Production ramped to 1,000L reactors to establish costing parameters for licensees = Pur

  10. Slide 10: Poultry Product Validation & Licensing

    e . . . . ZiVvo Poultry Product Validation & Licensing Betctnee . Discovery Stage Licensing Candidate Biotech ee * Study #18 validates significantly y campers streamlined product formulation Tolerance testing of purification processes in Study #19 yields valuable direction for larger validation stud

  11. Slide 11: Porcine Product Validation & Licensing

    e Bi otech Molecules Compounds Complexes Biotechnolog y: ZzIve Porcine Product Validation & Licensing Sones Discovery Stage Licensing Candidate = Study #2 to is docketed to commence after poultry licensing is closed = Initially, studies are targeting gut health and gut-related maladies = Weanlings a

  12. Slide 12: Bovine Applications & Licensing

    Bovine Applications & Licensing Free Biotech Discovery Stage Licensing Candidate Biotechnolog pean a = Research resumes after poultry and swine y Gonplenss licenses are executed = Bovine mastitis remains primary target = Oral administration unlikely = May be reprioritized below canine Test

  13. Slide 13: Human Applications & Licensing

    B i otech Molecules Compounds Complexes Biotechnolog iv: ZzIve Human Applications & Licensing Sore Discovery Stage Licensing Candidate = Positive preliminary testing provides direction for future research = Immune and inflammation primary targets = Initially, sepsis and arthritis R&D focus = May be

  14. Slide 14: Human Applications Development: Topical Skin Health

    AgTech*Sicc"" Agricultural Technology Dry Mixes ZzIve Human Applications Development Sore Topical Skin Health Candidate Product development launched mid 2020 Initial analysis indicates potential benefits Algal paste product candidate passes USDA stain and irritant test (SIT) Algal paste passes USP 5

  15. Slide 15: Skin Health Candidate: Clinical Efficacy Testing

    AgTech* Sic" Agricultural Technology Dry Mixes ZzIve Human Applications Development Sones Topical Skin Health Candidate Clinical efficacy testing is very promising Reduced fine wrinkles by 51.98% Reduced skin pore size by 38.76% Additional test planned over the next several weeks

  16. Slide 16: Skin Health Candidate: Clinical Efficacy Testing

    AgTech* ize" Agricultural Technology Dry Mixes ZzIve Human Applications Development Sore Topical Skin Health Candidate Clinical efficacy testing is very promising Reduced fine wrinkles by 51.98% Reduced skin pore size by 38.76% Additional test planned over the next several weeks

  17. Slide 17: Human Applications Development: Skin Health Candidate

    e Human Applications Development Frdoee igal i _— Skin Health Candidate AgTech ew. = Algal extract formulated as topical serum Agricultural TechnoonyD ay Mixes = Proprietary facial mist formulated and tested in focus group = All products share the same compliance pathway = Low-volume/high-margin pro

  18. Slide 18: Algal Biomass Production: Building Production Volume

    zive e Algal Biomass Production Bioscience TT vo See Building Production Volume ae = Phase 1 contract with Alimenta Al Agricultural Teceny a iy Mixes er contract wi Imenta Algae, = Phase 1 contract extension for buildout now in negotiations = Vidalgas groundbreaking delayed due to unusually wet weat

  19. Slide 19: Algal Biomass Production

    °e Algal Biomass Production ZzIve BIOSCIENCE ZIVO plans a global algae production network and derive revenues from selling biomass and joint ventures that market formulated products featuring ZIVO natural biomass E products AgTec! Igal Biomass Extracts Agricultural Technology Dry Mixes #1 Skin Healt

  20. Slide 20: Florida Mid-Scale Process Laboratory

    ZzIve BIOSCIENCE Florida Mid-Scale Process Laboratory Supplies growers with inoculum, technical and scientific support Mid-scale process optimization for photobioreactors and pond systems New photobioreactors in startup mode Houses ZIVO algal cultures and various lots of dried algal biomass QA/QC be

  21. Slide 21: COVID-19 Related Delays

    ZzIve °e COVID -19 Related Delays Soaclence Biotech AgTech Virtualized Research & Development = R&D spread across multiple universities, labs, contract research organizations Biotechnolog = Agricultural Technology = Personnel shortages, schedule backups affecting ZIVO research network = Supply chain

  22. Slide 22: Q&A

    2021 Annual Shareholder Meeting Q&A ZIVa Fascence

  23. Slide 23: Thank You

    2021 Annual Shareholder Meeting THANK YOU October 12, 2021 Detroit, Michigan

ZIVO Bioscience — Shareholder Meeting (October 2021) on 6ix